{
    "Rank": 677,
    "Study": {
        "ProtocolSection": {
            "IdentificationModule": {
                "NCTId": "NCT00176488",
                "OrgStudyIdInfo": {
                    "OrgStudyId": "CDR0000539565"
                },
                "SecondaryIdInfoList": {
                    "SecondaryIdInfo": [
                        {
                            "SecondaryId": "P30CA072720",
                            "SecondaryIdType": "U.S. NIH Grant/Contract",
                            "SecondaryIdLink": "https://reporter.nih.gov/quickSearch/P30CA072720"
                        },
                        {
                            "SecondaryId": "CINJ 040302",
                            "SecondaryIdType": "Other Identifier",
                            "SecondaryIdDomain": "Cancer Institute of New Jersey"
                        }
                    ]
                },
                "Organization": {
                    "OrgFullName": "Rutgers, The State University of New Jersey",
                    "OrgClass": "OTHER"
                },
                "BriefTitle": "Epirubicin and Vinorelbine in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer",
                "OfficialTitle": "A Phase II Trial of Sequential Epirubicin/Vinorelbine in Patients With Advanced Breast Cancer"
            },
            "StatusModule": {
                "StatusVerifiedDate": "February 2017",
                "OverallStatus": "Terminated",
                "WhyStopped": "Competing studies",
                "ExpandedAccessInfo": {
                    "HasExpandedAccess": "No"
                },
                "StartDateStruct": {
                    "StartDate": "June 2003"
                },
                "PrimaryCompletionDateStruct": {
                    "PrimaryCompletionDate": "October 2009",
                    "PrimaryCompletionDateType": "Actual"
                },
                "CompletionDateStruct": {
                    "CompletionDate": "October 2009",
                    "CompletionDateType": "Actual"
                },
                "StudyFirstSubmitDate": "September 12, 2005",
                "StudyFirstSubmitQCDate": "September 12, 2005",
                "StudyFirstPostDateStruct": {
                    "StudyFirstPostDate": "September 15, 2005",
                    "StudyFirstPostDateType": "Estimate"
                },
                "ResultsFirstSubmitDate": "September 18, 2013",
                "ResultsFirstSubmitQCDate": "September 18, 2013",
                "ResultsFirstPostDateStruct": {
                    "ResultsFirstPostDate": "November 25, 2013",
                    "ResultsFirstPostDateType": "Estimate"
                },
                "LastUpdateSubmitDate": "February 20, 2017",
                "LastUpdatePostDateStruct": {
                    "LastUpdatePostDate": "March 23, 2017",
                    "LastUpdatePostDateType": "Actual"
                }
            },
            "SponsorCollaboratorsModule": {
                "ResponsibleParty": {
                    "ResponsiblePartyType": "Sponsor"
                },
                "LeadSponsor": {
                    "LeadSponsorName": "University of Medicine and Dentistry of New Jersey",
                    "LeadSponsorClass": "OTHER"
                },
                "CollaboratorList": {
                    "Collaborator": [
                        {
                            "CollaboratorName": "National Cancer Institute (NCI)",
                            "CollaboratorClass": "NIH"
                        }
                    ]
                }
            },
            "OversightModule": {
                "OversightHasDMC": "No"
            },
            "DescriptionModule": {
                "BriefSummary": "RATIONALE: Drugs used in chemotherapy, such as epirubicin and vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving epirubicin together with vinorelbine may kill more tumor cells.\n\nPURPOSE: This phase II trial is studying how well giving epirubicin together with vinorelbine works in treating patients with stage II, stage III, or stage IV breast cancer.",
                "DetailedDescription": "OBJECTIVES:\n\nAssess the efficacy of sequential use of epirubicin hydrochloride followed by vinorelbine ditartrate in patients with stage IIB, IIIA, IIIB, or IV breast cancer.\nMeasure the biological response to this regimen in sequential tumor biopsies and peripheral mononuclear cells from these patients.\nCorrelate tumor response with changes in the gene expression of microtubule-associated protein 4.\n\nOUTLINE: Patients receive epirubicin hydrochloride IV on day 1 and vinorelbine ditartrate IV over 6-10 minutes on days 3 and 17. Patients also receive filgrastim (G-CSF) subcutaneously on days 4-14 or pegfilgrastim IV on day 4.\n\nFor patients with stage IIB (T3, N0), IIIA, or IIIB disease, treatment repeats every 21 days for up to 5 courses in the absence of disease progression or unacceptable toxicity. For patients with stage IV disease, treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.\n\nBlood samples are collected at baseline and after course 1 for research studies. Patients with accessible tumor for biopsy undergo sequential biopsies and core needle biopsies at baseline and after course 1. Tumor tissue samples are used for determination of p53 status by western blot analysis, immunohistochemistry, and DNA sequencing. Microtubule-associated protein 4, p53, and p21/WAF1 expression is analyzed by western blotting.\n\nAfter completion of study treatment, patients are followed for 1 month.\n\nPROJECTED ACCRUAL: A total of 46 patients will be accrued for this study."
            },
            "ConditionsModule": {
                "ConditionList": {
                    "Condition": [
                        "Breast Cancer"
                    ]
                },
                "KeywordList": {
                    "Keyword": [
                        "recurrent breast cancer",
                        "stage II breast cancer",
                        "stage IIIA breast cancer",
                        "stage IIIB breast cancer",
                        "stage IV breast cancer",
                        "male breast cancer"
                    ]
                }
            },
            "DesignModule": {
                "StudyType": "Interventional",
                "PhaseList": {
                    "Phase": [
                        "Phase 2"
                    ]
                },
                "DesignInfo": {
                    "DesignAllocation": "N/A",
                    "DesignInterventionModel": "Single Group Assignment",
                    "DesignPrimaryPurpose": "Treatment",
                    "DesignMaskingInfo": {
                        "DesignMasking": "None (Open Label)"
                    }
                },
                "EnrollmentInfo": {
                    "EnrollmentCount": "31",
                    "EnrollmentType": "Actual"
                }
            },
            "ArmsInterventionsModule": {
                "ArmGroupList": {
                    "ArmGroup": [
                        {
                            "ArmGroupLabel": "Sequential epirubicin/vinorelbine",
                            "ArmGroupType": "Experimental",
                            "ArmGroupDescription": "For patients with stage IIB (T3N0), IIIA, or IIIB breast cancer, epirubicin and vinorelbine will be administered for up to 5 cycles. For patients with stage IV breast cancer, epirubicin and vinorelbine will be administered as long as there is evidence of continued response or stable disease and no evidence of cardiac or other serious toxicities.",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Drug: epirubicin",
                                    "Drug: vinorelbine"
                                ]
                            }
                        }
                    ]
                },
                "InterventionList": {
                    "Intervention": [
                        {
                            "InterventionType": "Drug",
                            "InterventionName": "epirubicin",
                            "InterventionDescription": "Epirubicin (100 mg/m2) will be given on Day 1",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Sequential epirubicin/vinorelbine"
                                ]
                            },
                            "InterventionOtherNameList": {
                                "InterventionOtherName": [
                                    "epirubicin hydrochloride"
                                ]
                            }
                        },
                        {
                            "InterventionType": "Drug",
                            "InterventionName": "vinorelbine",
                            "InterventionDescription": "Vinorelbine (18.75 mg/m2) will be given on Days 3 and 17.",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Sequential epirubicin/vinorelbine"
                                ]
                            },
                            "InterventionOtherNameList": {
                                "InterventionOtherName": [
                                    "vinorelbine ditartrate"
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomesModule": {
                "PrimaryOutcomeList": {
                    "PrimaryOutcome": [
                        {
                            "PrimaryOutcomeMeasure": "Efficacy of the Sequential Use of a DNA Damaging Drug (Epirubicin) Followed by a Vinca Alkaloid (Vinorelbine) in the Treatment of Breast Cancer.",
                            "PrimaryOutcomeTimeFrame": "10 years"
                        }
                    ]
                },
                "SecondaryOutcomeList": {
                    "SecondaryOutcome": [
                        {
                            "SecondaryOutcomeMeasure": "Biological Response to Epirubicin and Vinorelbine Administered in Patients With Breast Cancer in Sequential Tumor Biopsies and Peripheral Blood Mononuclear Cells.",
                            "SecondaryOutcomeTimeFrame": "10 years"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Correlate Tumor Response With Changes in the Gene Expression of Microtubule Associated Protein 4 (MAP4).",
                            "SecondaryOutcomeTimeFrame": "10 years"
                        }
                    ]
                }
            },
            "EligibilityModule": {
                "EligibilityCriteria": "DISEASE CHARACTERISTICS:\n\nHistologically confirmed stage IIB (T3, N0), IIIA, IIIB, or IV breast carcinoma\nOriginal tumor must be available for analysis of p53 status\n\nMeasurable disease, defined as any lesion that can be accurately measured in \u2265 1 dimension with longest diameter \u2265 20 mm using conventional techniques OR \u2265 10 mm with spiral CT scan\n\nStage IIIB disease will be assessed by clinical exam (monitoring skin changes as well as tumor size)\nNo visceral crisis (lymphangitic pulmonary spread, or liver or marrow replacement sufficient to cause significant organ dysfunction)\nNo untreated CNS metastases\nHormone receptor status not specified\n\nPATIENT CHARACTERISTICS:\n\nMenopausal status not specified\nECOG performance status 0-2\nLife expectancy \u2265 8 weeks\nAbsolute neutrophil count \u2265 1,000/mm\u00b3\nPlatelet count \u2265 100,000/mm\u00b3\nHemoglobin \u2265 10 g/dL\nBilirubin normal\nAST \u2264 3 times normal (\u2264 5 times normal if liver metastases are present)\nCreatinine \u2264 1.5 mg/dL\nEjection fraction \u2265 lower limit of normal by MUGA scan or ECG\nNot pregnant or nursing\nNegative pregnancy test\nFertile patients must use effective nonhormonal contraception\nNo other malignancy except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer\nNo pre-existing disease (i.e., cardiac, pulmonary, neurologic, or other disease) that the investigator judges to be clinically significant\nNo active infectious process, severe malnutrition, or intractable emesis\n\nPRIOR CONCURRENT THERAPY:\n\nRecovered from all prior therapy\nAt least 3 weeks since prior radiotherapy\n\nAt least 3 weeks since prior chemotherapy\n\nMaximum prior doxorubicin hydrochloride dose must be \u2264 300 mg/m\u00b2 OR equivalent anthracycline (epirubicin hydrochloride) dose must be \u2264 540 mg/m\u00b2 OR calculated total anthracycline dose must be \u2264 540 mg/m\u00b2 (determined as 1.8 times total doxorubicin hydrochloride dose plus epirubicin hydrochloride dose)\nNo prior chemotherapy for metastatic disease\nPrior adjuvant chemotherapy, radiotherapy, and/or hormonal therapy for breast cancer allowed\nNo concurrent radiotherapy except for brain metastases",
                "HealthyVolunteers": "No",
                "Gender": "All",
                "MinimumAge": "21 Years",
                "MaximumAge": "120 Years",
                "StdAgeList": {
                    "StdAge": [
                        "Adult",
                        "Older Adult"
                    ]
                }
            },
            "ContactsLocationsModule": {
                "OverallOfficialList": {
                    "OverallOfficial": [
                        {
                            "OverallOfficialName": "Deborah L. Toppmeyer, MD",
                            "OverallOfficialAffiliation": "Rutgers Cancer Institute of New Jersey",
                            "OverallOfficialRole": "Principal Investigator"
                        }
                    ]
                },
                "LocationList": {
                    "Location": [
                        {
                            "LocationFacility": "Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School",
                            "LocationCity": "New Brunswick",
                            "LocationState": "New Jersey",
                            "LocationZip": "08903",
                            "LocationCountry": "United States"
                        }
                    ]
                }
            }
        },
        "ResultsSection": {
            "ParticipantFlowModule": {
                "FlowRecruitmentDetails": "Subjects were recruited from the Cancer Institute of New Jersey (a comprehensive cancer center) from June 2003 through May 2009.",
                "FlowGroupList": {
                    "FlowGroup": [
                        {
                            "FlowGroupId": "FG000",
                            "FlowGroupTitle": "Sequential Epirubicin/Vinorelbine",
                            "FlowGroupDescription": "For patients with stage IIB (T3N0), IIIA, or IIIB breast cancer, epirubicin and vinorelbine will be administered for up to 5 cycles. For patients with stage IV breast cancer, epirubicin and vinorelbine will be administered as long as there is evidence of continued response or stable disease and no evidence of cardiac or other serious toxicities.\n\nepirubicin : Epirubicin (100 mg/m2) will be given on Day 1\n\nvinorelbine : Vinorelbine (18.75 mg/m2) will be given on Days 3 and 17.\n\nBeginning on cycle 1, patients will receive G-CSF (Neupogen) at a dose of 5 mcg/kg on Day 4 of treatment for 10 days OR pegfilgrastim (Neulasta) 6 mg on Day 4 of treatment."
                        }
                    ]
                },
                "FlowPeriodList": {
                    "FlowPeriod": [
                        {
                            "FlowPeriodTitle": "Overall Study",
                            "FlowMilestoneList": {
                                "FlowMilestone": [
                                    {
                                        "FlowMilestoneType": "STARTED",
                                        "FlowAchievementList": {
                                            "FlowAchievement": [
                                                {
                                                    "FlowAchievementGroupId": "FG000",
                                                    "FlowAchievementNumSubjects": "31"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "FlowMilestoneType": "COMPLETED",
                                        "FlowAchievementList": {
                                            "FlowAchievement": [
                                                {
                                                    "FlowAchievementGroupId": "FG000",
                                                    "FlowAchievementNumSubjects": "30"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "FlowMilestoneType": "NOT COMPLETED",
                                        "FlowAchievementList": {
                                            "FlowAchievement": [
                                                {
                                                    "FlowAchievementGroupId": "FG000",
                                                    "FlowAchievementNumSubjects": "1"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "FlowDropWithdrawList": {
                                "FlowDropWithdraw": [
                                    {
                                        "FlowDropWithdrawType": "Initiated Cycle 1 Day 1 only",
                                        "FlowReasonList": {
                                            "FlowReason": [
                                                {
                                                    "FlowReasonGroupId": "FG000",
                                                    "FlowReasonNumSubjects": "1"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "BaselineCharacteristicsModule": {
                "BaselineGroupList": {
                    "BaselineGroup": [
                        {
                            "BaselineGroupId": "BG000",
                            "BaselineGroupTitle": "Sequential Epirubicin/Vinorelbine",
                            "BaselineGroupDescription": "For patients with stage IIB (T3N0), IIIA, or IIIB breast cancer, epirubicin and vinorelbine will be administered for up to 5 cycles. For patients with stage IV breast cancer, epirubicin and vinorelbine will be administered as long as there is evidence of continued response or stable disease and no evidence of cardiac or other serious toxicities.\n\nepirubicin : Epirubicin (100 mg/m2) will be given on Day 1\n\nvinorelbine : Vinorelbine (18.75 mg/m2) will be given on Days 3 and 17."
                        }
                    ]
                },
                "BaselineDenomList": {
                    "BaselineDenom": [
                        {
                            "BaselineDenomUnits": "Participants",
                            "BaselineDenomCountList": {
                                "BaselineDenomCount": [
                                    {
                                        "BaselineDenomCountGroupId": "BG000",
                                        "BaselineDenomCountValue": "31"
                                    }
                                ]
                            }
                        }
                    ]
                },
                "BaselineMeasureList": {
                    "BaselineMeasure": [
                        {
                            "BaselineMeasureTitle": "Age, Categorical",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineCategoryTitle": "<=18 years",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Between 18 and 65 years",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "28"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": ">=65 years",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "3"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Age, Continuous",
                            "BaselineMeasureParamType": "Mean",
                            "BaselineMeasureDispersionType": "Standard Deviation",
                            "BaselineMeasureUnitOfMeasure": "years",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "50.0",
                                                                "BaselineMeasurementSpread": "10.6"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Sex: Female, Male",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineCategoryTitle": "Female",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "31"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Male",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Region of Enrollment",
                            "BaselineMeasureParamType": "Number",
                            "BaselineMeasureUnitOfMeasure": "participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineClassTitle": "United States",
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "31"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomeMeasuresModule": {
                "OutcomeMeasureList": {
                    "OutcomeMeasure": [
                        {
                            "OutcomeMeasureType": "Primary",
                            "OutcomeMeasureTitle": "Efficacy of the Sequential Use of a DNA Damaging Drug (Epirubicin) Followed by a Vinca Alkaloid (Vinorelbine) in the Treatment of Breast Cancer.",
                            "OutcomeMeasurePopulationDescription": "Study was closed prematurely and insufficient data was collected.",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureTimeFrame": "10 years",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "Sequential Epirubicin/Vinorelbine",
                                        "OutcomeGroupDescription": "For patients with stage IIB (T3N0), IIIA, or IIIB breast cancer, epirubicin and vinorelbine will be administered for up to 5 cycles. For patients with stage IV breast cancer, epirubicin and vinorelbine will be administered as long as there is evidence of continued response or stable disease and no evidence of cardiac or other serious toxicities.\n\nepirubicin : Epirubicin (100 mg/m2) will be given on Day 1\n\nvinorelbine : Vinorelbine (18.75 mg/m2) will be given on Days 3 and 17."
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "0"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "OutcomeMeasureType": "Secondary",
                            "OutcomeMeasureTitle": "Biological Response to Epirubicin and Vinorelbine Administered in Patients With Breast Cancer in Sequential Tumor Biopsies and Peripheral Blood Mononuclear Cells.",
                            "OutcomeMeasurePopulationDescription": "Study was closed prematurely and insufficient data was collected.",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureTimeFrame": "10 years",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "Sequential Epirubicin/Vinorelbine",
                                        "OutcomeGroupDescription": "For patients with stage IIB (T3N0), IIIA, or IIIB breast cancer, epirubicin and vinorelbine will be administered for up to 5 cycles. For patients with stage IV breast cancer, epirubicin and vinorelbine will be administered as long as there is evidence of continued response or stable disease and no evidence of cardiac or other serious toxicities.\n\nepirubicin : Epirubicin (100 mg/m2) will be given on Day 1\n\nvinorelbine : Vinorelbine (18.75 mg/m2) will be given on Days 3 and 17."
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "0"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "OutcomeMeasureType": "Secondary",
                            "OutcomeMeasureTitle": "Correlate Tumor Response With Changes in the Gene Expression of Microtubule Associated Protein 4 (MAP4).",
                            "OutcomeMeasurePopulationDescription": "Study was closed prematurely and insufficient data was collected.",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureTimeFrame": "10 years",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "Sequential Epirubicin/Vinorelbine",
                                        "OutcomeGroupDescription": "For patients with stage IIB (T3N0), IIIA, or IIIB breast cancer, epirubicin and vinorelbine will be administered for up to 5 cycles. For patients with stage IV breast cancer, epirubicin and vinorelbine will be administered as long as there is evidence of continued response or stable disease and no evidence of cardiac or other serious toxicities.\n\nepirubicin : Epirubicin (100 mg/m2) will be given on Day 1\n\nvinorelbine : Vinorelbine (18.75 mg/m2) will be given on Days 3 and 17."
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "0"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "AdverseEventsModule": {
                "EventsFrequencyThreshold": "5",
                "EventsTimeFrame": "5 years and 6 months",
                "EventGroupList": {
                    "EventGroup": [
                        {
                            "EventGroupId": "EG000",
                            "EventGroupTitle": "Sequential Epirubicin/Vinorelbine",
                            "EventGroupDescription": "For patients with stage IIB (T3N0), IIIA, or IIIB breast cancer, epirubicin and vinorelbine will be administered for up to 5 cycles. For patients with stage IV breast cancer, epirubicin and vinorelbine will be administered as long as there is evidence of continued response or stable disease and no evidence of cardiac or other serious toxicities.\n\nepirubicin : Epirubicin (100 mg/m2) will be given on Day 1\n\nvinorelbine : Vinorelbine (18.75 mg/m2) will be given on Days 3 and 17.",
                            "EventGroupSeriousNumAffected": "14",
                            "EventGroupSeriousNumAtRisk": "31",
                            "EventGroupOtherNumAffected": "31",
                            "EventGroupOtherNumAtRisk": "31"
                        }
                    ]
                },
                "SeriousEventList": {
                    "SeriousEvent": [
                        {
                            "SeriousEventTerm": "Hemoglobin",
                            "SeriousEventOrganSystem": "Blood and lymphatic system disorders",
                            "SeriousEventSourceVocabulary": "CTCAE (2.0)",
                            "SeriousEventAssessmentType": "Non-systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "1",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "Platelets",
                            "SeriousEventOrganSystem": "Blood and lymphatic system disorders",
                            "SeriousEventSourceVocabulary": "CTCAE (2.0)",
                            "SeriousEventAssessmentType": "Non-systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "1",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "Thrombosis/embolism",
                            "SeriousEventOrganSystem": "Vascular disorders",
                            "SeriousEventSourceVocabulary": "CTCAE (2.0)",
                            "SeriousEventAssessmentType": "Non-systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "1",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "Fatigue (lethargy, malaise, asthenia)",
                            "SeriousEventOrganSystem": "General disorders",
                            "SeriousEventSourceVocabulary": "CTCAE (2.0)",
                            "SeriousEventAssessmentType": "Non-systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "1",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "Fever (in the absence of neutropenia, where neutropenia is defined as AGC<1.0 x 10e9/L)",
                            "SeriousEventOrganSystem": "General disorders",
                            "SeriousEventSourceVocabulary": "CTCAE (2.0)",
                            "SeriousEventAssessmentType": "Non-systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "1",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "Anorexia",
                            "SeriousEventOrganSystem": "Gastrointestinal disorders",
                            "SeriousEventSourceVocabulary": "CTCAE (2.0)",
                            "SeriousEventAssessmentType": "Non-systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "1",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "Stomatitis/pharyngitis (oral/pharyngeal mucositis)",
                            "SeriousEventOrganSystem": "Gastrointestinal disorders",
                            "SeriousEventSourceVocabulary": "CTCAE (2.0)",
                            "SeriousEventAssessmentType": "Non-systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "1",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "Febrile neutropenia (fever of unknown origin without clinically or microbiologically documented infe",
                            "SeriousEventOrganSystem": "General disorders",
                            "SeriousEventSourceVocabulary": "CTCAE (2.0)",
                            "SeriousEventAssessmentType": "Non-systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "14",
                                        "SeriousEventStatsNumAffected": "12",
                                        "SeriousEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "Infection (documented clinically or microbiologically) with grade 3 or 4 neutropenia (ANC <1.0 x 10e",
                            "SeriousEventOrganSystem": "Infections and infestations",
                            "SeriousEventSourceVocabulary": "CTCAE (2.0)",
                            "SeriousEventAssessmentType": "Non-systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "1",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "Infection without neutropenia",
                            "SeriousEventOrganSystem": "Infections and infestations",
                            "SeriousEventSourceVocabulary": "CTCAE (2.0)",
                            "SeriousEventAssessmentType": "Non-systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "1",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "Syncope (fainting)",
                            "SeriousEventOrganSystem": "Nervous system disorders",
                            "SeriousEventSourceVocabulary": "CTCAE (2.0)",
                            "SeriousEventAssessmentType": "Non-systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "1",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "Dyspnea (shortness of breath)",
                            "SeriousEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
                            "SeriousEventSourceVocabulary": "CTCAE (2.0)",
                            "SeriousEventAssessmentType": "Non-systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "1",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "Pneumothorax",
                            "SeriousEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
                            "SeriousEventSourceVocabulary": "CTCAE (2.0)",
                            "SeriousEventAssessmentType": "Non-systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "1",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "Pulmonary-Other (Specify, malignant pleural effusion)",
                            "SeriousEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
                            "SeriousEventSourceVocabulary": "CTCAE (2.0)",
                            "SeriousEventAssessmentType": "Non-systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "1",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "Other Toxicity - Bilateral Pleural effusion",
                            "SeriousEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
                            "SeriousEventSourceVocabulary": "CTCAE (2.0)",
                            "SeriousEventAssessmentType": "Non-systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "1",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        }
                    ]
                },
                "OtherEventList": {
                    "OtherEvent": [
                        {
                            "OtherEventTerm": "Alopecia",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventSourceVocabulary": "CTCAE (2.0)",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "39",
                                        "OtherEventStatsNumAffected": "29",
                                        "OtherEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Nail changes",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventSourceVocabulary": "CTCAE (2.0)",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "6",
                                        "OtherEventStatsNumAffected": "6",
                                        "OtherEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Dermatology/Skin-Other (Specify,_____)",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventSourceVocabulary": "CTCAE (2.0)",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "6",
                                        "OtherEventStatsNumAffected": "5",
                                        "OtherEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Bruising (in absence of grade 3 or 4 thrombocytopenia)",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventSourceVocabulary": "CTCAE (2.0)",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "2",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Nausea",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventSourceVocabulary": "CTCAE (2.0)",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "48",
                                        "OtherEventStatsNumAffected": "26",
                                        "OtherEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Constipation",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventSourceVocabulary": "CTCAE (2.0)",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "33",
                                        "OtherEventStatsNumAffected": "15",
                                        "OtherEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Stomatitis/pharyngitis (oral/pharyngeal mucositis)",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventSourceVocabulary": "CTCAE (2.0)",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "24",
                                        "OtherEventStatsNumAffected": "15",
                                        "OtherEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Taste disturbance (dysgeusia)",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventSourceVocabulary": "CTCAE (2.0)",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "17",
                                        "OtherEventStatsNumAffected": "13",
                                        "OtherEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Vomiting",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventSourceVocabulary": "CTCAE (2.0)",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "16",
                                        "OtherEventStatsNumAffected": "10",
                                        "OtherEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Dyspepsia/heartburn",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventSourceVocabulary": "CTCAE (2.0)",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "13",
                                        "OtherEventStatsNumAffected": "9",
                                        "OtherEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Anorexia",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventSourceVocabulary": "CTCAE (2.0)",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "14",
                                        "OtherEventStatsNumAffected": "8",
                                        "OtherEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Diarrhea patients without colostomy",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventSourceVocabulary": "CTCAE (2.0)",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "9",
                                        "OtherEventStatsNumAffected": "7",
                                        "OtherEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Gastrointestinal-Other (Specify,_____)",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventSourceVocabulary": "CTCAE (2.0)",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "5",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Dysphagia, esophagitis, odynophagia (painful swallowing)",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventSourceVocabulary": "CTCAE (2.0)",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "5",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Fatigue (lethargy, malaise, asthenia)",
                            "OtherEventOrganSystem": "General disorders",
                            "OtherEventSourceVocabulary": "CTCAE (2.0)",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "55",
                                        "OtherEventStatsNumAffected": "25",
                                        "OtherEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Fever (in the absence of neutropenia, where neutropenia is defined as AGC<1.0 x 10e9/L)",
                            "OtherEventOrganSystem": "General disorders",
                            "OtherEventSourceVocabulary": "CTCAE (2.0)",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "7",
                                        "OtherEventStatsNumAffected": "7",
                                        "OtherEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Pain-Other (Specify,___)",
                            "OtherEventOrganSystem": "General disorders",
                            "OtherEventSourceVocabulary": "CTCAE (2.0)",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "36",
                                        "OtherEventStatsNumAffected": "18",
                                        "OtherEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Bone pain",
                            "OtherEventOrganSystem": "General disorders",
                            "OtherEventSourceVocabulary": "CTCAE (2.0)",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "6",
                                        "OtherEventStatsNumAffected": "6",
                                        "OtherEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Myalgia (muscle pain)",
                            "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
                            "OtherEventSourceVocabulary": "CTCAE (2.0)",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "8",
                                        "OtherEventStatsNumAffected": "5",
                                        "OtherEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Headache",
                            "OtherEventOrganSystem": "General disorders",
                            "OtherEventSourceVocabulary": "CTCAE (2.0)",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "5",
                                        "OtherEventStatsNumAffected": "4",
                                        "OtherEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Abdominal pain or cramping",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventSourceVocabulary": "CTCAE (2.0)",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "3",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Arthralgia (joint pain)",
                            "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
                            "OtherEventSourceVocabulary": "CTCAE (2.0)",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "2",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Chest pain (non-cardiac and non-pleuritic)",
                            "OtherEventOrganSystem": "General disorders",
                            "OtherEventSourceVocabulary": "CTCAE (2.0)",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "2",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Hemoglobin",
                            "OtherEventOrganSystem": "Blood and lymphatic system disorders",
                            "OtherEventSourceVocabulary": "CTCAE (2.0)",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "68",
                                        "OtherEventStatsNumAffected": "23",
                                        "OtherEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Platelets",
                            "OtherEventOrganSystem": "Blood and lymphatic system disorders",
                            "OtherEventSourceVocabulary": "CTCAE (2.0)",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "20",
                                        "OtherEventStatsNumAffected": "11",
                                        "OtherEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Neutrophils/granulocytes (ANC/AGC)",
                            "OtherEventOrganSystem": "Blood and lymphatic system disorders",
                            "OtherEventSourceVocabulary": "CTCAE (2.0)",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "27",
                                        "OtherEventStatsNumAffected": "10",
                                        "OtherEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Blood/Bone Marrow-Other (Specify,_____)",
                            "OtherEventOrganSystem": "Blood and lymphatic system disorders",
                            "OtherEventSourceVocabulary": "CTCAE (2.0)",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "10",
                                        "OtherEventStatsNumAffected": "4",
                                        "OtherEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Neuropathy-sensory",
                            "OtherEventOrganSystem": "Nervous system disorders",
                            "OtherEventSourceVocabulary": "CTCAE (2.0)",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "14",
                                        "OtherEventStatsNumAffected": "10",
                                        "OtherEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Insomnia",
                            "OtherEventOrganSystem": "Nervous system disorders",
                            "OtherEventSourceVocabulary": "CTCAE (2.0)",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "7",
                                        "OtherEventStatsNumAffected": "7",
                                        "OtherEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Dizziness/lightheadedness",
                            "OtherEventOrganSystem": "Nervous system disorders",
                            "OtherEventSourceVocabulary": "CTCAE (2.0)",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "9",
                                        "OtherEventStatsNumAffected": "6",
                                        "OtherEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Mood alteration-anxiety, agitation",
                            "OtherEventOrganSystem": "Psychiatric disorders",
                            "OtherEventSourceVocabulary": "CTCAE (2.0)",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "4",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Dyspnea (shortness of breath)",
                            "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
                            "OtherEventSourceVocabulary": "CTCAE (2.0)",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "18",
                                        "OtherEventStatsNumAffected": "11",
                                        "OtherEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Cough",
                            "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
                            "OtherEventSourceVocabulary": "CTCAE (2.0)",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "7",
                                        "OtherEventStatsNumAffected": "6",
                                        "OtherEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Hyperglycemia",
                            "OtherEventOrganSystem": "Investigations",
                            "OtherEventSourceVocabulary": "CTCAE (2.0)",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "10",
                                        "OtherEventStatsNumAffected": "6",
                                        "OtherEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Hypokalemia",
                            "OtherEventOrganSystem": "Investigations",
                            "OtherEventSourceVocabulary": "CTCAE (2.0)",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "8",
                                        "OtherEventStatsNumAffected": "6",
                                        "OtherEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Hyponatremia",
                            "OtherEventOrganSystem": "Investigations",
                            "OtherEventSourceVocabulary": "CTCAE (2.0)",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "4",
                                        "OtherEventStatsNumAffected": "4",
                                        "OtherEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Metabolic/Laboratory-Other (Specify,_____)",
                            "OtherEventOrganSystem": "Investigations",
                            "OtherEventSourceVocabulary": "CTCAE (2.0)",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "6",
                                        "OtherEventStatsNumAffected": "4",
                                        "OtherEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Hypocalcemia",
                            "OtherEventOrganSystem": "Investigations",
                            "OtherEventSourceVocabulary": "CTCAE (2.0)",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "3",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Febrile neutropenia (fever of unknown origin without clinically or microbiologically documented infe",
                            "OtherEventOrganSystem": "General disorders",
                            "OtherEventSourceVocabulary": "CTCAE (2.0)",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "11",
                                        "OtherEventStatsNumAffected": "9",
                                        "OtherEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Infection without neutropenia",
                            "OtherEventOrganSystem": "Infections and infestations",
                            "OtherEventSourceVocabulary": "CTCAE (2.0)",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "2",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Edema",
                            "OtherEventOrganSystem": "Vascular disorders",
                            "OtherEventSourceVocabulary": "CTCAE (2.0)",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "11",
                                        "OtherEventStatsNumAffected": "9",
                                        "OtherEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Hypotension",
                            "OtherEventOrganSystem": "Cardiac disorders",
                            "OtherEventSourceVocabulary": "CTCAE (2.0)",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "2",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Alkaline phosphatase",
                            "OtherEventOrganSystem": "Hepatobiliary disorders",
                            "OtherEventSourceVocabulary": "CTCAE (2.0)",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "9",
                                        "OtherEventStatsNumAffected": "7",
                                        "OtherEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "SGOT (AST) (serum glutamic oxaloacetic transaminase)",
                            "OtherEventOrganSystem": "Hepatobiliary disorders",
                            "OtherEventSourceVocabulary": "CTCAE (2.0)",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "3",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "SGPT (ALT) (serum glutamic pyruvic transaminase)",
                            "OtherEventOrganSystem": "Hepatobiliary disorders",
                            "OtherEventSourceVocabulary": "CTCAE (2.0)",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "2",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Hot flashes/flushes",
                            "OtherEventOrganSystem": "Endocrine disorders",
                            "OtherEventSourceVocabulary": "CTCAE (2.0)",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "4",
                                        "OtherEventStatsNumAffected": "4",
                                        "OtherEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Tearing (watery eyes)",
                            "OtherEventOrganSystem": "Eye disorders",
                            "OtherEventSourceVocabulary": "CTCAE (2.0)",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "2",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Urinary frequency/urgency",
                            "OtherEventOrganSystem": "Renal and urinary disorders",
                            "OtherEventSourceVocabulary": "CTCAE (2.0)",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "2",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Hemorrhage-Other (Specify,_____)",
                            "OtherEventOrganSystem": "Blood and lymphatic system disorders",
                            "OtherEventSourceVocabulary": "CTCAE (2.0)",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "3",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "31"
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "MoreInfoModule": {
                "CertainAgreement": {
                    "AgreementPISponsorEmployee": "Yes"
                },
                "PointOfContact": {
                    "PointOfContactTitle": "Deborah Toppmeyer, MD",
                    "PointOfContactOrganization": "Cancer Institute of New Jersey",
                    "PointOfContactEMail": "toppmede@cinj.rutgers.edu; rizzoji@cinj.rutgers.edu; zelinsta@cinj.rutgers.edu",
                    "PointOfContactPhone": "732-235-8675"
                }
            }
        },
        "DerivedSection": {
            "MiscInfoModule": {
                "VersionHolder": "September 08, 2023"
            },
            "ConditionBrowseModule": {
                "ConditionMeshList": {
                    "ConditionMesh": [
                        {
                            "ConditionMeshId": "D000001943",
                            "ConditionMeshTerm": "Breast Neoplasms"
                        }
                    ]
                },
                "ConditionAncestorList": {
                    "ConditionAncestor": [
                        {
                            "ConditionAncestorId": "D000009371",
                            "ConditionAncestorTerm": "Neoplasms by Site"
                        },
                        {
                            "ConditionAncestorId": "D000009369",
                            "ConditionAncestorTerm": "Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000001941",
                            "ConditionAncestorTerm": "Breast Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000012871",
                            "ConditionAncestorTerm": "Skin Diseases"
                        }
                    ]
                },
                "ConditionBrowseLeafList": {
                    "ConditionBrowseLeaf": [
                        {
                            "ConditionBrowseLeafId": "M4910",
                            "ConditionBrowseLeafName": "Breast Neoplasms",
                            "ConditionBrowseLeafAsFound": "Breast Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M14540",
                            "ConditionBrowseLeafName": "Recurrence",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M20355",
                            "ConditionBrowseLeafName": "Breast Neoplasms, Male",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M4908",
                            "ConditionBrowseLeafName": "Breast Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M15364",
                            "ConditionBrowseLeafName": "Skin Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "T861",
                            "ConditionBrowseLeafName": "Breast Cancer, Male",
                            "ConditionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "ConditionBrowseBranchList": {
                    "ConditionBrowseBranch": [
                        {
                            "ConditionBrowseBranchAbbrev": "BC04",
                            "ConditionBrowseBranchName": "Neoplasms"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC17",
                            "ConditionBrowseBranchName": "Skin and Connective Tissue Diseases"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "All",
                            "ConditionBrowseBranchName": "All Conditions"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC23",
                            "ConditionBrowseBranchName": "Symptoms and General Pathology"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "Rare",
                            "ConditionBrowseBranchName": "Rare Diseases"
                        }
                    ]
                }
            },
            "InterventionBrowseModule": {
                "InterventionMeshList": {
                    "InterventionMesh": [
                        {
                            "InterventionMeshId": "D000077235",
                            "InterventionMeshTerm": "Vinorelbine"
                        },
                        {
                            "InterventionMeshId": "D000015251",
                            "InterventionMeshTerm": "Epirubicin"
                        }
                    ]
                },
                "InterventionAncestorList": {
                    "InterventionAncestor": [
                        {
                            "InterventionAncestorId": "D000000972",
                            "InterventionAncestorTerm": "Antineoplastic Agents, Phytogenic"
                        },
                        {
                            "InterventionAncestorId": "D000000970",
                            "InterventionAncestorTerm": "Antineoplastic Agents"
                        },
                        {
                            "InterventionAncestorId": "D000050257",
                            "InterventionAncestorTerm": "Tubulin Modulators"
                        },
                        {
                            "InterventionAncestorId": "D000050256",
                            "InterventionAncestorTerm": "Antimitotic Agents"
                        },
                        {
                            "InterventionAncestorId": "D000050258",
                            "InterventionAncestorTerm": "Mitosis Modulators"
                        },
                        {
                            "InterventionAncestorId": "D000045504",
                            "InterventionAncestorTerm": "Molecular Mechanisms of Pharmacological Action"
                        },
                        {
                            "InterventionAncestorId": "D000000903",
                            "InterventionAncestorTerm": "Antibiotics, Antineoplastic"
                        },
                        {
                            "InterventionAncestorId": "D000059005",
                            "InterventionAncestorTerm": "Topoisomerase II Inhibitors"
                        },
                        {
                            "InterventionAncestorId": "D000059003",
                            "InterventionAncestorTerm": "Topoisomerase Inhibitors"
                        },
                        {
                            "InterventionAncestorId": "D000004791",
                            "InterventionAncestorTerm": "Enzyme Inhibitors"
                        }
                    ]
                },
                "InterventionBrowseLeafList": {
                    "InterventionBrowseLeaf": [
                        {
                            "InterventionBrowseLeafId": "M1710",
                            "InterventionBrowseLeafName": "Vinorelbine",
                            "InterventionBrowseLeafAsFound": "Allogeneic",
                            "InterventionBrowseLeafRelevance": "high"
                        },
                        {
                            "InterventionBrowseLeafId": "M17644",
                            "InterventionBrowseLeafName": "Epirubicin",
                            "InterventionBrowseLeafAsFound": "Reduced",
                            "InterventionBrowseLeafRelevance": "high"
                        },
                        {
                            "InterventionBrowseLeafId": "M25887",
                            "InterventionBrowseLeafName": "Tubulin Modulators",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M25886",
                            "InterventionBrowseLeafName": "Antimitotic Agents",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M3912",
                            "InterventionBrowseLeafName": "Anti-Bacterial Agents",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M3914",
                            "InterventionBrowseLeafName": "Antibiotics, Antitubercular",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M7641",
                            "InterventionBrowseLeafName": "Enzyme Inhibitors",
                            "InterventionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "InterventionBrowseBranchList": {
                    "InterventionBrowseBranch": [
                        {
                            "InterventionBrowseBranchAbbrev": "ANeo",
                            "InterventionBrowseBranchName": "Antineoplastic Agents"
                        },
                        {
                            "InterventionBrowseBranchAbbrev": "All",
                            "InterventionBrowseBranchName": "All Drugs and Chemicals"
                        },
                        {
                            "InterventionBrowseBranchAbbrev": "Infe",
                            "InterventionBrowseBranchName": "Anti-Infective Agents"
                        }
                    ]
                }
            }
        }
    }
}